原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C54H82N14O22S2 |
InChIKeyHZQYFECPKQJXFX-DAHMAOPXSA-N |
CAS号2014384-91-7 |
开始日期2020-10-23 |
申办/合作机构- |
开始日期2020-09-23 |
申办/合作机构 |
开始日期2020-07-15 |
申办/合作机构- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
新型冠状病毒感染 | 临床前 | 比利时 | 2020-07-06 | |
脓毒性休克 | 临床前 | 美国 | 2017-06-22 | |
心肌梗塞 | 临床前 | 法国 | - |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床2期 | 220 | (艱獵蓋齋襯獵鏇壓鏇顧): odds ratio = 1.79 (95% CI, 1.02 ~ 3.14), P-Value = 0.043 | 积极 | 2023-06-01 | |||
Placebo | |||||||
临床2期 | 355 | (壓製壓鬱窪構願構積構) = 鏇壓積淵觸窪襯鹽衊醖 艱糧餘獵壓鑰顧鏇衊齋 (構蓋鹽憲齋製窪鬱願遞 ) | 不佳 | 2023-05-31 | |||
(壓製壓鬱窪構願構積構) = 廠鏇窪製網鹽淵壓艱願 艱糧餘獵壓鑰顧鏇衊齋 (構蓋鹽憲齋製窪鬱願遞 ) | |||||||
临床2期 | 220 | 廠築艱膚醖壓壓網範淵(鬱衊蓋蓋夢窪鑰築範餘): P-Value = 0.040 更多 | 积极 | 2022-10-25 | |||
Placebo | |||||||
临床2期 | - | (艱餘鹽簾醖獵鏇簾簾鹽) = the benefit of nangibotide high dose treatment versus placebo was clinically and statistically significant at higher concentrations of sTREM-1, representing about 50% of the study population 鬱艱鑰襯顧選淵糧膚蓋 (願膚構鹹壓艱鹹襯糧築 ) | 积极 | 2022-10-13 | |||
Standard of Care | |||||||
临床1期 | 27 | (鏇願糧鑰範壓鏇糧壓醖) = There were only few adverse events and they were mild in severity and considered unrelated to treatment 顧積壓壓網憲齋憲廠蓋 (鬱淵網構膚鹹範鏇鏇繭 ) | - | 2018-10-01 |